| Nov 21 |
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
|
| Nov 21 |
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics
|
| Nov 14 |
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
|
| Nov 10 |
Cartesian Therapeutics: Uncertainty Remains
|
| Nov 7 |
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 5 |
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
|
| Oct 18 |
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock
|
| Oct 15 |
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
|
| Sep 17 |
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
|
| Sep 9 |
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
|
